Biomarkers of Acrylamide, Glycidol, POPs, PFAS and Disease Outcomes and OMICs Signatures

The aim of the project is to assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with persistent organic pollutants (POPs) and per- and polyflouroalkyl substances (PFAS) using a prospective cohort study utilizing and integrating various 'OMICs' technologies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Disease Cancer Cardiovascular Diseases Environmental Exposure Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

60YO: Men and women of 60 years old residing in Stockholm
SMC-C: Women residing in Uppsala

Exclusion criteria

Subjects will be excluded if they had the outcome under investigation at baseline

Treatment and study plan

Biomarkers of acrylamide, glycidol, POPs, PFAS

Other

These are food contaminants (acrylamide, glycidol) and environmental pollutants (POPs, PFAS). Assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with POPs and PFAS using a prospective cohort study utilizing and integrating various 'OMICs' technologies.

Primary outcomes

Cardiovascular disease

Time frame: From baseline beginning in 2003 through 2017

Using International Classification of Diseases (ICD) codes to assess cardiovascular disease (CVD) incidence (myocardial infarction and stroke, ICD10: I21 and I63)
Cancer

Time frame: From baseline (2003 for SMC-C and 1997 for 60YO) until the latest available follow-up, currently 2021

Using ICD codes to assess cancer (such as ICD-10: C18, C20, C50, C54)

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

The Swedish Research Council

Registry information

Important dates

Study start: 1997
Primary completion: 2008
Study completion: 2008
First posted: Jul 5, 2023
Registry last updated: Jul 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting